- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00467493
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
June 2, 2009 updated by: Meditrina Pharmaceuticals
A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole, an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)
Aromatase inhibitors have been approved for use in postmenopausal women to treat and prevent breast cancer.
They act by blocking the action of the enzyme, aromatase, that is necessary for the production of estradiol.
This class of drugs, aromatase inhibitors, are very effective in reducing estradiol levels in postmenopausal women and in treating estrogen receptor positive breast cancers.
This study is examining the effect of a specific inhibitor, anastrozole, on endometrial thickness in premenopausal women.
The endometrium is sensitive to estradiol and also has local aromatase which, if inhibited, may result in reduced endometrial thickness.
The main hypothesis is that anastrozole can be administered at any time during the menstrual cycle and reduce endometrial thickness compared to placebo.
Study Overview
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49007
- Jasper Research Clinic
-
Southfield, Michigan, United States, 48034
- University Women's Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Between the ages of 25 and 45 and pre-menopausal;
- Non-lactating and not pregnant
- able to follow the schedule of procedures
- able to freely provide informed consent
- have clinically acceptable physical examination and safety laboratory studies
Exclusion Criteria:
- current use of any form of systemic contraceptive
- have self-reported irregular menstrual cycles
- intercurrent illness(es) detected on the screening physical
- unwilling or unable to use barrier methods of contraception
- have evidence of endometrial polyps or myomata on TVU/SIS that would interfere with endometrial thickness measurement
- detection of ovarian cyst(s) during adnexal examination on screening TVU/SIS measuring greater than 5 cm
- have history of, or current cancer, on any form exclusive of basal cell carcinoma
- BMI >= 35
- history of alcohol or drug abuse in the past 5 years
- unwilling or unable to undergo study procedures within the necessary time frames
- history or current liver abnormalities as defined by ALT or AST > 2X ULN
- treated or untreated diabetes defined as fasting blood sugar >= 126 mg/dL
- untreated hypertension
- impaired renal function by estimated creatinine clearance < 80mL/min
- have estradiol levels < 20 pg/ml and FSH levels > 40 mIU/mL or
- have a history of adverse reaction any aromatase inhibitor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anastrozole - A
Treatment for 26 consecutive days
|
|
Experimental: Anastrozole -B
Treatment for 7 consecutive days early in menstrual cycle
|
|
Experimental: Anastrozoe - C
Treatment for 7 consecutive days mid follicular phase
|
|
Experimental: Anastrozole - D
Treatment for 7 consecutive days - mid cycle
|
|
Experimental: Anastrozole - E
Treatment for 7 consecutive days - luteal
|
|
Placebo Comparator: Anastrozole - F
Treatment with placebo for 26 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Endometrial thickness as measured by transvaginal ultrasound, safety
Time Frame: Over one menstrual cycle
|
Over one menstrual cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
April 27, 2007
First Submitted That Met QC Criteria
April 27, 2007
First Posted (Estimate)
April 30, 2007
Study Record Updates
Last Update Posted (Estimate)
June 3, 2009
Last Update Submitted That Met QC Criteria
June 2, 2009
Last Verified
June 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Menstruation Disturbances
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Anastrozole
Other Study ID Numbers
- M-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menstruation Disorders
-
Clinical Research Centre, MalaysiaTwin Catalyst Sdn. Bhd.Completed
-
National Institute of Environmental Health Sciences...CompletedEndocrine Dysfunction | Menstruation Disorders | Fecundability | Spermatazoa DisordersChina
-
Bandırma Onyedi Eylül UniversityCompletedIrregular Menstruation | Pre-MenopauseTurkey
-
University of California, San FranciscoOrtho-McNeil, Inc.WithdrawnMenstruation Disturbances | Dysmenorrhea | Menstruation Disorders
-
Institut National de la Santé Et de la Recherche...Not yet recruiting
-
Institut National de la Santé Et de la Recherche...Unknown
-
University of British ColumbiaNational Research System-College of Family Physicians of CanadaCompleted
-
Pamukkale UniversityRecruitingMenstruation; SyndromeTurkey
Clinical Trials on Anastrozole
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruitingAdvanced Breast CancerChina
-
The Affiliated Hospital of Qingdao UniversityUnknownBioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed ConditionHealthy VolunteersChina
-
Massachusetts General HospitalTerminatedKallmann Syndrome | Hypogonadotropic HypogonadismUnited States
-
The Affiliated Hospital of Qingdao UniversityUnknown
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Trans Tasman Radiation Oncology GroupActive, not recruitingBreast CancerAustralia, New Zealand
-
Havah Therapeutics Pty LtdCompletedMammographic DensityAustralia
-
Massachusetts General HospitalNational Institute on Aging (NIA)Completed
-
Havah Therapeutics Pty LtdGTxCompletedMammographic DensityAustralia